Artelo Biosciences Reports Increased Losses Amid Strategic Investments

Artelo Biosciences ( (ARTL) ) has released its Q2 earnings. Here is a breakdown of the information Artelo Biosciences presented to its investors.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system, with operations in the United States, Ireland, the UK, and Canada.

In its latest earnings report for the quarter ending June 30, 2025, Artelo Biosciences reported a comprehensive loss of $3.3 million, an increase from the $2.4 million loss in the same period last year, reflecting higher operating expenses and strategic investments.

Key financial metrics revealed a rise in operating expenses to $3.15 million, driven by increased general and administrative costs and research and development expenses. The company also reported a net loss of $5.6 million for the six months ended June 30, 2025, compared to $4.9 million in the prior year. Despite these losses, Artelo Biosciences raised $1.8 million through financing activities, including convertible notes and private placements, to support its ongoing operations.

Looking ahead, Artelo Biosciences remains focused on advancing its clinical programs and exploring additional funding opportunities to sustain its operations and achieve its strategic objectives in the biopharmaceutical sector.